Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Circulating leukocyte-platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents.
Zamora C, Riudavets M, Anguera G, Alserawan L, Sullivan I, Barba A, Serra J, Ortiz MA, Gallardo P, Perea L, Gavira J, Barnadas A, Majem M, Vidal S. Zamora C, et al. Among authors: anguera g. Cancer Immunol Immunother. 2021 Jun;70(6):1691-1704. doi: 10.1007/s00262-020-02793-4. Epub 2021 Jan 2. Cancer Immunol Immunother. 2021. PMID: 33388994 Free PMC article.
Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents.
Riudavets M, Mosquera J, Garcia-Campelo R, Serra J, Anguera G, Gallardo P, Sullivan I, Barba A, Del Carpio L, Barnadas A, Gich I, Majem M. Riudavets M, et al. Among authors: anguera g. Front Oncol. 2020 Sep 7;10:1677. doi: 10.3389/fonc.2020.01677. eCollection 2020. Front Oncol. 2020. PMID: 33014837 Free PMC article.
The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents.
Zamora Atenza C, Anguera G, Riudavets Melià M, Alserawan De Lamo L, Sullivan I, Barba Joaquin A, Serra Lopez J, Ortiz MA, Mulet M, Vidal S, Majem M. Zamora Atenza C, et al. Among authors: anguera g. Cancer Immunol Immunother. 2022 Aug;71(8):1823-1835. doi: 10.1007/s00262-021-03107-y. Epub 2022 Jan 5. Cancer Immunol Immunother. 2022. PMID: 34984538 Free PMC article.
Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events.
Alserawan L, Anguera G, Zamora Atenza C, Serra López J, Martínez-Martínez L, Riudavets Melià M, Sullivan I, Barba Joaquin A, Majem Tarruella M, Vidal S. Alserawan L, et al. Among authors: anguera g. Int J Mol Sci. 2022 Oct 20;23(20):12641. doi: 10.3390/ijms232012641. Int J Mol Sci. 2022. PMID: 36293498 Free PMC article.
Cumulative incidences of hypogonadism, hypertension, and dyslipidaemia in patients with stage I seminoma treated with a risk-adapted strategy: a Spanish single-centre retrospective analysis.
Tapia JC, Gavira J, Anguera G, Sanchez S, Romano A, Bosma F, Molina A, Sanz-Beltran J, Martin-Lorente C, Algaba F, Maroto P. Tapia JC, et al. Among authors: anguera g. Clin Transl Oncol. 2024 Jul;26(7):1798-1803. doi: 10.1007/s12094-024-03393-9. Epub 2024 Feb 29. Clin Transl Oncol. 2024. PMID: 38421563
66 results